Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestlé
Lucien Selce and MKT Capital , owning 1.4 million shares of Seres Therapeutics (NASDAQ: MCRB), have issued an open letter to the company's Board of Directors. The letter expresses concern over a media report suggesting Seres rejected a takeover offer from Nestlé for $6.00 - $6.50 per share, instead opting to sell its VOWST business to Nestlé Health Science.
The shareholders are requesting immediate clarification from the Board regarding its engagement with Nestlé, citing potential violation of fiduciary duty if the report is accurate. They highlight that Nestlé's reported offer would have represented a 622% premium to Seres' current stock price. The letter emphasizes the urgency of the matter, as the VOWST sale is set to close on September 30, 2024.
Lucien Selce e MKT Capital, che possiedono 1,4 milioni di azioni di Seres Therapeutics (NASDAQ: MCRB), hanno inviato una lettera aperta al Consiglio di Amministrazione dell'azienda. Nella lettera esprimono preoccupazione per un rapporto dei media che suggerisce che Seres ha rifiutato un'offerta di acquisto da parte di Nestlé tra $6.00 e $6.50 per azione, optando invece per la vendita della sua attività VOWST a Nestlé Health Science.
Gli azionisti richiedono immediata chiarificazione da parte del Consiglio riguardo al suo coinvolgimento con Nestlé, citando una potenziale violazione del dovere fiduciario se il rapporto fosse accurato. Sottolineano che l'offerta riportata di Nestlé rappresenterebbe un 622% di premio rispetto al prezzo attuale delle azioni di Seres. La lettera sottolinea l'urgenza della questione, poiché la vendita di VOWST è prevista per chiudere il 30 settembre 2024.
Lucien Selce y MKT Capital, que poseen 1.4 millones de acciones de Seres Therapeutics (NASDAQ: MCRB), han emitido una carta abierta a la Junta Directiva de la compañía. La carta expresa preocupación por un informe de los medios que sugiere que Seres rechazó una oferta de adquisición de Nestlé por entre $6.00 y $6.50 por acción, optando en su lugar por vender su negocio VOWST a Nestlé Health Science.
Los accionistas están solicitando una aclaración inmediata de la Junta sobre su relación con Nestlé, citando una posible violación del deber fiduciario si el informe es exacto. Subrayan que la oferta reportada de Nestlé habría representado un 622% de prima sobre el precio actual de las acciones de Seres. La carta enfatiza la urgencia del asunto, ya que se espera que la venta de VOWST se cierre el 30 de septiembre de 2024.
루시앙 셀스(Lucien Selce)와 MKT 캐피탈(MKT Capital)은 세레스 테라퓨틱스(NASDAQ: MCRB)의 140만 주를 소유하고 있으며, 회사의 이사회에 공개 서한을 발송했습니다. 서한에서는 세레스가 네슬레로부터 주당 6.00~6.50달러의 인수 제안을 거부하고, 대신 VOWST 사업을 네슬레 헬스 사이언스에 판매하기로 선택했다는 언론 보도에 대한 우려를 표명하고 있습니다.
주주들은 이사회에 네슬레와의 관계에 대해 즉각적인 설명을 요청하고 있으며, 보도가 정확하다면 신탁 의무의 잠재적 위반을 언급하고 있습니다. 그들은 네슬레의 제안이 세레스의 현재 주가에 대해 622%의 프리미엄을 의미했을 것이라고 강조하고 있습니다. 이 서한은 VOWST 매각이 2024년 9월 30일에 마감될 예정임에 따라 긴급성을 강조하고 있습니다.
Lucien Selce et MKT Capital, qui détiennent 1,4 million d'actions de Seres Therapeutics (NASDAQ: MCRB), ont adressé une lettre ouverte au Conseil d'Administration de l'entreprise. La lettre exprime des inquiétudes concernant un rapport médiatique suggérant que Seres a rejeté une offre de rachat de Nestlé entre 6,00 et 6,50 $ par action, optant plutôt pour la vente de son activité VOWST à Nestlé Health Science.
Les actionnaires demandent une clarification immédiate du Conseil sur son implication avec Nestlé, citant une possible violation de l'obligation fiduciaire si le rapport est exact. Ils soulignent que l'offre rapportée de Nestlé aurait représenté une 622% de prime par rapport au prix actuel des actions de Seres. La lettre souligne l'urgence de la situation, car la vente de VOWST devrait se conclure le 30 septembre 2024.
Lucien Selce und MKT Capital, die 1,4 Millionen Aktien von Seres Therapeutics (NASDAQ: MCRB) besitzen, haben einen offenen Brief an den Vorstand des Unternehmens geschickt. Der Brief äußert Bedenken über einen Medienbericht, der nahelegt, dass Seres ein Übernahmeangebot von Nestlé in Höhe von 6,00 bis 6,50 USD pro Aktie abgelehnt hat und stattdessen beschlossen hat, sein VOWST-Geschäft an Nestlé Health Science zu verkaufen.
Die Aktionäre fordern sofortige Klarstellung vom Vorstand bezüglich seiner Engagements mit Nestlé und erwähnen eine mögliche Verletzung der Treuhandpflicht, falls der Bericht zutrifft. Sie betonen, dass das gemeldete Angebot von Nestlé einen 622% Aufschlag auf den aktuellen Aktienkurs von Seres dargestellt hätte. Der Brief hebt die Dringlichkeit der Angelegenheit hervor, da der Verkauf von VOWST voraussichtlich am 30. September 2024 abgeschlossen wird.
- Potential for a significant premium (622%) on stock price if Nestlé's reported offer is accurate
- Shareholders actively seeking transparency and maximization of value
- Alleged rejection of a takeover offer that could have benefited shareholders
- Concerns about the company's ability to fund operations and turn around in the public market
- Negative stock price reaction to the VOWST sale agreement announcement
- Potential legal action against the Board for violating fiduciary duty
Express Concern Regarding Report That Seres Allegedly Rebuffed an Outright Takeover Offer from Nestlé for
Request that the Board Immediately Provide Stockholders With the Facts Regarding Its Engagement With Nestlé Ahead of the September 30th Closing of the VOWST Sale
***
September 27, 2024
Members of the Board,
We are writing to you today as a stockholder of Seres who is seeking additional information regarding the Company’s planned sale of its VOWST business to Nestlé Health Science.
We have read a recent media report from Betaville which states that Nestlé S.A. (“Nestlé”) approached Seres in July 2024 with an offer to acquire the entire Company for between
This concerns us because Nestlé’s offer would have represented a more than
If this media report is accurate, that would mean the Board violated its fiduciary duty to stockholders – specifically, its duty to maximize stockholder value – and could be held legally liable. We acknowledge that this information stems from a singular media report, which is why we are asking the Board to provide stockholders with a factual assessment of the contents of the report so that we may make fully informed decisions regarding our investment in the Company.
If you do not address my concerns in a timely fashion, we plan to consider all legal remedies under
Time is of the essence, as Seres intends to close the VOWST sale to Nestlé on September 30, 2024. We look forward to hearing from you soon.
Sincerely,
Lucien Selce |
|
Antoine Khalife |
|
|
|
MKT Capital Ltd. |
|
____________________
1 The Company’s stock closed at
2 The Company’s stock closed at
View source version on businesswire.com: https://www.businesswire.com/news/home/20240927387718/en/
Lucien Selce
Lucienselce@gmail.com
Source: On behalf of a Concerned Stockholder Group
FAQ
What is the reported takeover offer for Seres Therapeutics (MCRB) from Nestlé?
Why are Seres Therapeutics (MCRB) shareholders concerned about the VOWST sale?
When is the VOWST sale between Seres Therapeutics (MCRB) and Nestlé Health Science expected to close?
What action are the concerned shareholders of Seres Therapeutics (MCRB) considering?
